<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060199</url>
  </required_header>
  <id_info>
    <org_study_id>NS-065/NCNP-01-301</org_study_id>
    <nct_id>NCT04060199</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NS Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nippon Shinyaku Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NS Pharma, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy of Viltolarsen compared to&#xD;
      placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess&#xD;
      the efficacy and safety of Viltolarsen in ambulant boys with Duchenne muscular dystrophy.&#xD;
      Eligible patients with out-of-frame deletion mutations amenable to exon 53 skipping will be&#xD;
      randomized to receive once weekly intravenous (IV) infusions of 80 mg/kg Viltolarsen or&#xD;
      placebo for up to 48 weeks.&#xD;
&#xD;
      The study will enroll approximately 74 patients amenable to exon 53 skipping. Clinical&#xD;
      efficacy will be assessed at regularly scheduled study visits, including functional tests&#xD;
      such as Time to Stand Test (TTSTAND), Time to Run/Walk 10 Meters Test (TTRW), Six-minute Walk&#xD;
      Test (6MWT), North Star Ambulatory Assessment (NSAA), Time to Climb 4 Steps Test (TTCLIMB)&#xD;
      and Hand-held dynamometer (elbow extension, elbow flexion, knee extension and knee flexion on&#xD;
      the dominant side only).&#xD;
&#xD;
      Safety will be assessed through the collection of adverse events (AEs), laboratory tests,&#xD;
      electrocardiograms (ECGs), vital signs, and physical examinations throughout the study.&#xD;
&#xD;
      Blood samples will be taken periodically throughout the study to assess the pharmacokinetics&#xD;
      of study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TTSTAND</measure>
    <time_frame>baseline to 48 weeks of treatment</time_frame>
    <description>Change in Time to Stand (TTSTAND)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TTRW</measure>
    <time_frame>baseline to 48 weeks of treatment</time_frame>
    <description>Change in Time to Run/Walk 10 Meters Test (TTRW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWT</measure>
    <time_frame>baseline to 48 weeks of treatment</time_frame>
    <description>Change in Six-minutes Walk Test (6MWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NSAA</measure>
    <time_frame>baseline to 48 weeks of treatment</time_frame>
    <description>Change in North Star Ambulatory Assessment (NSAA)&#xD;
The NSAA is a functional scale devised for use in ambulant children with Duchenne muscular dystrophy (DMD). It consists of 17 activities graded 0 (unable to perform), 1 (performs with modifications), 2 (normal movement). It assesses abilities necessary to remain ambulant that have been found to progressively deteriorate in untreated DMD patients, as well as in other muscular dystrophies such as Becker Muscular Dystrophy. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTCLIMB</measure>
    <time_frame>baseline to 48 weeks of treatment</time_frame>
    <description>Change in Time to Climb 4 Steps Test (TTCLIMB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand-held dynamometer</measure>
    <time_frame>baseline to 48 weeks of treatment</time_frame>
    <description>The force generated for each muscle strength (elbow extension, elbow flexion, knee extension, and knee flexion on the dominant side only) will be measured by Hand-held dynamometer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Viltolarsen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viltolarsen</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Viltolarsen</arm_group_label>
    <other_name>NS-065/NCNP-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male ≥ 4 years and &lt; 8 years of age&#xD;
&#xD;
          -  Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon&#xD;
             53 to restore the dystrophin mRNA reading frame&#xD;
&#xD;
          -  Able to walk independently without assistive devices&#xD;
&#xD;
          -  TTSTAND &lt; 10 seconds&#xD;
&#xD;
          -  Stable dose of glucocorticoid (GC) for at least 3 months prior to study entry and is&#xD;
             expected to remain on stable dose of GC treatment for the duration of the study&#xD;
&#xD;
          -  Other inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of chronic systemic fungal or viral infections&#xD;
&#xD;
          -  Acute illness within 4 weeks prior to the first dose of study drug&#xD;
&#xD;
          -  Evidence of symptomatic cardiomyopathy (Note: Asymptomatic cardiac abnormality on&#xD;
             investigation would not be exclusionary)&#xD;
&#xD;
          -  Allergy or hypersensitivity to the study drug or to any of its constituents&#xD;
&#xD;
          -  Severe behavioral or cognitive problems that preclude participation in the study, in&#xD;
             the opinion of the investigator&#xD;
&#xD;
          -  Previous or ongoing medical condition, medical history, physical findings or&#xD;
             laboratory abnormalities that could affect safety, make it unlikely that treatment and&#xD;
             follow-up will be correctly completed or impair the assessment of study results, in&#xD;
             the opinion of the investigator;&#xD;
&#xD;
          -  Surgery within the 3 months prior to the first dose of study drug or surgery is&#xD;
             planned for anytime during the duration of the study&#xD;
&#xD;
          -  Participant has positive test results for hepatitis B antigen, hepatitis C antibody or&#xD;
             human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Currently taking any other investigational drug or has taken any other investigational&#xD;
             drug within 3 months prior to the first dose of study drug or within 5 times the&#xD;
             half-life of a medication, whichever is longer&#xD;
&#xD;
          -  Previously enrolled in an interventional study of viltolarsen&#xD;
&#xD;
          -  Currently taking any other exon skipping agent or has taken any other exon skipping&#xD;
             agent within 3 months prior to the first dose of study drug&#xD;
&#xD;
          -  Having taken any gene therapy&#xD;
&#xD;
          -  Other exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Info</last_name>
    <phone>1-866-677-4276</phone>
    <email>trialinfo@nspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queensland Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Childrens Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children (SickKids)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec Research Centre</name>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Niños Roberto del Rio</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agia Sofia Children's Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hong Kong Children's Hospital</name>
      <address>
        <city>Kowloon Bay</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine College Hospital</name>
      <address>
        <city>Hyōgo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles Chihuahua</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Zealand Clinical Research Ltd</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medical University n.a. N.I.Pirogov, structural branch - Research Clinical Institute of Pediatrics n.a. Academician Yu. E. Veltishchev</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Saint Petersburg State Paediatric Medical University&quot; based at Consultative and Diagnostic Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tomsk National Research Medical Center of Russian Academy of Sciences</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeditepe University Kosuyolu Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Ukrainian Medical rehabilitation Center for Children with organic disorders of the nervous system of the Ministry of Health of Ukraine&quot;</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Children - Glasgow</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Institute of Child Health</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

